Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
You may also be interested in...
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Private equity investor Advent has acquired API maker ZCL Chemicals in India, its second transaction in a segment seeing rising interest as pharma de-risks sourcing for key ingredients post COVID-19-related turbulence.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.